Australian Clinical Labs Past Earnings Performance
Past criteria checks 1/6
Australian Clinical Labs's earnings have been declining at an average annual rate of -6.6%, while the Healthcare industry saw earnings declining at 3.3% annually. Revenues have been growing at an average rate of 7.5% per year. Australian Clinical Labs's return on equity is 13.6%, and it has net margins of 3.4%.
Key information
-6.6%
Earnings growth rate
-25.5%
EPS growth rate
| Healthcare Industry Growth | 2.4% |
| Revenue growth rate | 7.5% |
| Return on equity | 13.6% |
| Net Margin | 3.4% |
| Next Earnings Update | 26 Feb 2025 |
Recent past performance updates
Recent updates
Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge
Sep 03
Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?
Sep 02We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt
Jun 20Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?
Feb 21Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
Dec 08Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today
Aug 14Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)
Dec 22The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More
Dec 21The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business
Sep 01Revenue & Expenses Breakdown
How Australian Clinical Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 696 | 24 | 0 | 0 |
| 31 Mar 24 | 685 | 20 | 0 | 0 |
| 31 Dec 23 | 674 | 15 | 0 | 0 |
| 30 Sep 23 | 686 | 26 | 0 | 0 |
| 30 Jun 23 | 697 | 36 | 0 | 0 |
| 31 Mar 23 | 757 | 55 | 0 | 0 |
| 31 Dec 22 | 818 | 73 | 0 | 0 |
| 30 Sep 22 | 907 | 126 | 0 | 0 |
| 30 Jun 22 | 996 | 178 | 0 | 0 |
| 31 Mar 22 | 931 | 156 | 0 | 0 |
| 31 Dec 21 | 867 | 134 | 0 | 0 |
| 30 Sep 21 | 757 | 97 | 0 | 0 |
| 30 Jun 21 | 647 | 60 | 0 | 0 |
| 31 Mar 21 | 598 | 79 | 0 | 0 |
| 31 Dec 20 | 549 | 98 | 0 | 0 |
| 30 Sep 20 | 520 | 70 | 0 | 0 |
| 30 Jun 20 | 491 | 41 | 0 | 0 |
| 30 Jun 19 | 448 | -11 | 315 | 0 |
| 30 Jun 18 | 379 | -9 | 267 | 0 |
| 30 Jun 17 | 340 | -24 | 252 | 0 |
Quality Earnings: ACL has a large one-off loss of A$9.6M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: ACL's current net profit margins (3.4%) are lower than last year (5.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACL has become profitable over the past 5 years, growing earnings by -6.6% per year.
Accelerating Growth: ACL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ACL had negative earnings growth (-33.3%) over the past year, making it difficult to compare to the Healthcare industry average (-25.4%).
Return on Equity
High ROE: ACL's Return on Equity (13.6%) is considered low.